LAS VEGAS, Nov. 16, 2022 /PRNewswire/ -- DelveInsight's
' report provides comprehensive global coverage of available, marketed, and pipeline TIGIT inhibitorTIGIT inhibitor drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the TIGIT inhibitorsTIGIT inhibitors competitive domain. 20+ TIGIT inhibitorsTIGIT inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the TIGIT inhibitorsTIGIT inhibitors market would significantly increase market revenue. Vibostolimab, BMS 986442, Ociperlimab, Domvanalimab, EOS 448, Etigilimab, PH 804-TME, PH 804-ACT, BAT6005, Vibostolimab, M 6223, COM 902, BMS 986442, and others. September 13, 2022, Akeso, Inc., a China-based biopharmaceutical company focused on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, presented encouraging preclinical results in a poster featuring its Fc-mutant anti-TIGIT antibody fused with TGF-RII protein (AK130) at the European Society for Medical Oncology (ESMO) Congress 2022. December 2021, Bio-Thera Solutions, a commercial-stage pharmaceutical company, announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers. June 2021, GlaxoSmithKline and iTeos Therapeutics announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomized clinical trial. TIGIT-blockade clinical trials in cancer have recently begun in large numbers, mostly as combination treatments. TIGIT-Fc fusion protein has been shown to interact with PVR on dendritic cells, increase IL-10 secretion/decrease IL-12 secretion in response to LPS stimulation, and inhibit T cell activation in vivo. Antibodies against TIGIT's interaction with PVR can block its inhibition of NK cytotoxicity, and the activity is directed through its ITIM domain. BAT6005, developed by Bio-Thera Solutions, is a monoclonal antibody that targets TIGIT in cancer patient volunteers. BAT6005 was discovered using Bio-Thera's proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, and it has normal IgG1 ADCC function. Key TIGIT InhibitorsTIGIT Inhibitors Pipeline Therapies: Vibostolimab, BMS 986442, Ociperlimab, Domvanalimab, EOS 448, Etigilimab, PH 804-TME, PH 804-ACT, BAT6005, Vibostolimab, M 6223, COM 902, BMS 986442, and others. – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology current treatment practices, emerging drugs, and key non-small cell lung cancer companies, including – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-small cell lung cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Small-cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Small-cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key small-cell lung cancer companies, including – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key extensive stage small cell lung cancer companies, including Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd, Celgene, among others. US Healthcare Outlook Report
Negative Pressure Wound Therapy Systems Market
Dysfunctional Uterine Bleeding Market
Age-related Vision Dysfunction Market
CRISPR Therapies Pipeline Insight Drug Hypersensitivity Market
Weight Loss/Weight Management (Obesity) Market
Physiotherapy Equipment Market
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Radiofrequency Ablation Devices Market
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
Trastuzumab Biosimilars Insight
Intracardiac Echocardiography Devices Market
Injectable Drug Delivery Devices Market
Structural Heart Devices Market
Substance (Drug) Abuse Market
Global Healthcare Burden NSCLC Poses Related Healthcare Services
Healthcare Competitive Intelligence Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg